On February 9, 2025 TheraPPI Bioscience ("TheraPPI"), a preclinical biotechnology company focused on developing small molecules that modify protein interactions, reported the first closing of its Pre-Seed financing (Press release, TheraPPI, FEB 9, 2025, View Source [SID1234657194]). All investors have substantial experience in the biotech sector.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TheraPPI will use the proceeds today’s announced to advance the development of its lead program targeting ERK/MyD88, a novel protein interaction in the Ras-MAPK pathway to tackle cancer drug resistance and to offer more effective and safer therapies to patients with advanced cancers.
TheraPPI also announced the inception of TheraPPI Bioscience SA (Geneva, Switzerland) and the nomination of a Board of Directors of this new company. Patricia Delaite, MD, a clinical oncologist and executive in biotech companies, joins the company’s Board as Chairwoman. John Tchelingerian, PhD, a serial entrepreneur and private investor in the biotech sector, and Barthélemy Helg, LL. M. & MBA, an executive in the biotech and food tech sectors, join the company’s Board as independent Directors. Luc Otten, MD, PhD, founder CEO, and Toufic Renno, PhD, founder CSO of TheraPPI, are also Board Directors.
"TheraPPI is developing a first-in-class drug for bringing efficacious therapy to patients with cancer who can’t any longer benefit from modern targeted therapies or immunotherapies. TheraPPI lead program tackles a real unmet medical need by fighting cancer drug resistance, a major cause of death. I am deeply honoured to support TheraPPI on this exciting journey" said Patricia Delaite. "Thanks to the support of our new investors, our Board of Directors, and this open Pre-Seed financing round, we are moving forward by expediting TheraPPI’s lead program and preparing additional developments. The combination of long experience in both academia and industry from the team with strong corporate governance provides a solid foundation for future TheraPPI successes," added Luc Otten.